Generex Biotechnology Corp., of Toronto, said its subsidiary Antigen Express Inc. hired John Zinckgraf to accelerate development of a vaccine for pandemic influenza.

Genmab A/S, of Copenhagen, Denmark, appointed Bo Kruse vice president and interim chief financial officer.

Genome Canada, of Ottawa, Ontario, appointed Natalie Dakers, Connie Eaves, Thomas Hudson, Kelvin Ogilvie, Jacques Simard and Ronald Worton to its board.

GenoMed Inc., of St. Louis, appointed Richard Reece, Jack Gruninger and Chris Todd to its business development advisory board.

GlobeImmune Inc., of Denver, appointed Francis Chisari to its scientific advisory board.

ImpactRx Inc., of Mount Laurel, N.J., appointed David Arkowitz to its board.

Inhibitex Inc., of Atlanta, appointed Robert Hamm to its board.

Integrated BioPharma Inc., of Hillside, N.J., appointed Eric Friedman acting chief financial officer.

Kalypsys Inc., of San Diego, appointed Paul Grint chief medical officer and head of development.

Labopharm Inc., of Laval, Quebec, appointed Richard MacKay interim chairman of its board.

LineaGen Research Corp., of Salt Lake City, promoted Michael Paul to president.

Milestone Scientific Inc., of Livingston, N.J., appointed Rosaline Shau chief financial officer.

Nabi Biopharmaceuticals, of Boca Raton, Fla., appointed Leslie Hudson to its board.

Nonlinear Dynamics Ltd., of Newcastle upon Tyne, UK, appointed Ian Currie European sales manager.

Northwest Biotherapeutics Inc., of Bothell, Wash., appointed Paul Zeltzer medical director.

Organon Pharmaceuticals USA Inc., of Roseland, N.J., named Robert Kaper vice president, medical affairs.

Osteotech Inc., of Eatontown, N.J., appointed Mark Burroughs to its board.

Oxigene Inc., of Waltham, Mass., appointed Richard Chin to its board.

Panacos Pharmaceuticals Inc., of Watertown, Mass., appointed Peyton Marshall executive vice president and chief financial officer.

PDI Inc., of Saddle River, N.J., appointed Jack Stover to its board and audit committee and Larry Ellberger executive vice president and chief administrative officer.

Pharmasset, of Princeton, N.J., appointed Loni da Silva vice president, regulatory affairs, and Michael Sofia vice president, chemistry.

PhytoMedical Technologies Inc., of Vancouver, British Columbia, appointed Harmel Rayat president and CEO.

Phyton Biotech Inc., of Fort Worth, Texas, appointed Michael Horn director of cell and molecular biology, Sarah Parekh director of cell culture process development, and Guillermo Touse director of chemistry.

Prana Biotechnology Ltd., of Melbourne, Australia, appointed Peter Marks nonexecutive director.

Protalex Inc., of New Hope, Pa., appointed Victor Sloan senior vice president and chief medical officer.

QLT Inc., of Vancouver, British Columbia, appointed Cameron Nelson vice president of finance and chief financial officer.

RheoGene Inc., of Norristown, Pa., appointed Fred Gage, Richard Gregory and Inder Verma to its scientific advisory board.

RiverVest Venture Partners, of St. Louis, appointed Dennis Wahr managing director.

Sirna Therapeutics Inc., of San Francisco, appointed Dennis Langer to its board.

Solexa Inc., of Hayward, Calif., appointed David Bentley chief scientist.

Structural GenomiX Inc., of San Diego, named James Rotherham chief financial officer, and Peter Myers vice president of drug discovery.

Tanox Inc., of Houston, appointed Linda Paradiso vice president of clinical operations and regulatory affairs.

Targeted Genetics Corp., of Seattle, appointed David Poston acting chief financial officer, and named Roger Hawley to its board.

Tercica Inc., of Brisbane, Calif., appointed Michael Astrue to its board.

Theratechnologies Inc., of Montreal, appointed Bernard Reculeau to its board.

TorreyPines Therapeutics, of San Diego, appointed Peter Davis to its board.

Unigen Pharmaceuticals Inc., of Lacey, Wash., appointed Regan Miles president and chief operating officer.

Viral Genetics Inc., of Azusa, Calif., appointed Wieslawa Giermakowska director of research.

Vyteris Holdings Inc., of Fair Lawn, N.J., appointed David Friend vice president of research, and Louise Galanos vice president of quality assurance.

No Comments